Tirzepatide (Mounjaro) Drug Interactions
Tirzepatide's most important interaction categories are oral contraceptives, insulin/sulfonylureas, oral medicines affected by gastric emptying, and risk-amplifying co-medications during dehydration. It is not primarily a CYP-mediated interaction drug; the mechanism is largely physiologic gastric-emptying delay and additive pharmacodynamic effects.
Tirzepatide's most important interaction categories are oral contraceptives, insulin/sulfonylureas, oral medicines affected by gastric emptying, and risk-amplifying co-medications during dehydration. It is not primarily a CYP-mediated interaction drug; the mechanism is largely physiologic gastric-emptying delay and additive pharmacodynamic effects.
Key Takeaways
- Tirzepatide is not primarily a CYP interaction drug, the main mechanism is gastric-emptying delay plus additive effects.
- The most important interactions are oral contraceptives and hypoglycemia with insulin or sulfonylureas.
- Most oral drugs are not expected to need automatic dose changes, though absorption may be delayed.
- Get a medication review if you take insulin, sulfonylureas, narrow-therapeutic-index drugs, contraceptive pills, or kidney-risk medicines.
- Report immediately: severe abdominal pain, persistent vomiting, hypoglycemia, allergic reaction, or pregnancy.
Tirzepatide Interactions at a Glance
| Property | Detail |
|---|---|
| Drug class | Dual GIP/GLP-1 receptor agonist (Mounjaro) |
| Main interaction mechanism | Physiologic gastric-emptying delay; additive pharmacodynamic effects |
| Highest-importance interactions | Oral contraceptives; insulin/sulfonylureas |
| CYP-mediated interactions? | Not a major feature |
| Who needs a medication review | Users of insulin, sulfonylureas, NTI drugs, oral contraceptives, or kidney-risk medicines |
How Tirzepatide Interacts
Tirzepatide slows gastric emptying, especially after initiation and dose escalation. This can delay the absorption of some oral drugs and is the basis of its oral-contraceptive precaution. It also adds to the glucose-lowering effect of insulin and sulfonylureas, and its GI effects can cause dehydration that amplifies the kidney risk of NSAIDs. It is not primarily a CYP-enzyme interaction drug.
On tirzepatide with other medicines?
Check your full medication list for the interactions that actually matter. Allmeds scans it in minutes.
Top Clinically Significant Interactions
| Interaction Category | Mechanism | Significance | Patient-Facing Advice |
|---|---|---|---|
| Oral contraceptives | Delayed gastric emptying may reduce oral-hormone absorption during initiation/escalation | High | Use non-oral or barrier backup for 4 weeks after start and each escalation |
| Insulin / sulfonylureas | Additive glucose-lowering | High | Clinician may reduce insulin/secretagogue dose; monitor glucose |
| Narrow-therapeutic-index oral drugs | Delayed absorption possible | Variable | Consider monitoring or pharmacist review |
| NSAIDs during dehydration | Additive kidney-injury risk | Moderate to high in susceptible patients | Avoid NSAIDs during vomiting/diarrhea unless advised |
| Alcohol | Additive GI, dehydration, and hypoglycemia concerns | Variable | Avoid heavy use and monitor intake |
Common Questions About Tirzepatide Interactions
Oral-contraceptive precautions and hypoglycemia with insulin/sulfonylureas are among the most important.
It may delay absorption, but most oral drugs are not expected to need automatic dose changes.
Gastric-emptying effects may be stronger after starting or escalating, increasing the contraceptive concern.
Yes if you take insulin, sulfonylureas, narrow-therapeutic-index drugs, contraceptive pills, or kidney-risk medicines.
Severe abdominal pain, persistent vomiting, hypoglycemia, allergic reaction, or pregnancy.
Check tirzepatide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic / Wegovy / Mounjaro EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.